Aligos Therapeutics Company Insiders
| ALGS Stock | USD 25.51 2.52 10.96% |
Aligos Therapeutics employs about 68 people. The company is managed by 12 executives with a total tenure of roughly 159 years, averaging almost 13.0 years of service per executive, having 5.67 employees per reported executive. Breaking down Aligos Therapeutics' management performance can provide insight into the firm performance.
Aligos |
Aligos Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6732) % which means that it has lost $0.6732 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4669) %, meaning that it created substantial loss on money invested by shareholders. Aligos Therapeutics' management efficiency ratios could be used to measure how well Aligos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.73 in 2024. At this time, Aligos Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 14.9 M in 2024, despite the fact that Other Assets are likely to grow to (2.3 M).Common Stock Shares Outstanding is likely to gain to about 33.9 M in 2024, whereas Net Loss is likely to drop (90.8 M) in 2024.
Aligos Therapeutics Workforce Comparison
Aligos Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 844. Aligos Therapeutics holds roughly 68.0 in number of employees claiming about 8% of equities under Health Care industry.
Aligos Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aligos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aligos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aligos Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.6154 | 21 | 13 | 2,325,829 | 1,343,213 |
| 2022-06-01 | 3.3333 | 10 | 3 | 150,000 | 332,274 |
| 2021-06-01 | 3.0 | 12 | 4 | 160,659 | 988,726 |
| 2020-12-01 | 1.1852 | 64 | 54 | 23,455,098 | 24,012,484 |
Aligos Therapeutics Notable Stakeholders
An Aligos Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aligos Therapeutics often face trade-offs trying to please all of them. Aligos Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aligos Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Dr MBA | President CEO | Profile | |
| Lesley CPA | Executive CFO | Profile | |
| TseI Lin | VP Head | Profile | |
| Leonid Beigelman | Pres Director | Profile | |
| Dr DABT | Executive Sciences | Profile | |
| Kristina Engeseth | Ex Culture | Profile | |
| Lucinda JD | Chief VP | Profile | |
| John Fry | Ex Devel | Profile | |
| Hardean MD | Chief Officer | Profile | |
| Julian DPHIL | Executive Officer | Profile | |
| Matthew MD | Executive Officer | Profile | |
| David Smith | Executive Operations | Profile |
About Aligos Therapeutics Management Performance
The success or failure of an entity such as Aligos Therapeutics often depends on how effective the management is. Aligos Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aligos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aligos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.69) | (0.73) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (0.95) | (0.90) |
Please note, the imprecision that can be found in Aligos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aligos Therapeutics. Check Aligos Therapeutics' Beneish M Score to see the likelihood of Aligos Therapeutics' management manipulating its earnings.
Aligos Therapeutics Workforce Analysis
Traditionally, organizations such as Aligos Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aligos Therapeutics within its industry.Aligos Therapeutics Manpower Efficiency
Return on Aligos Therapeutics Manpower
| Revenue Per Employee | 228.4K | |
| Revenue Per Executive | 1.3M | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 7.3M | |
| Working Capital Per Employee | 1.7M | |
| Working Capital Per Executive | 9.8M |
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.